Breast Cancer Guide on CD-ROM Is Available

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 6 No 5
Volume 6
Issue 5

DENVER--The AMC Cancer Research Center, through its Center of Excellence in Health Communications, has developed The Personal Guide to Breast Cancer, a multimedia CD-ROM guide to breast cancer prevention, detection, treatment, and resources, designed to be understood by the average layperson.

DENVER--The AMC Cancer Research Center, through its Center of Excellencein Health Communications, has developed The Personal Guide to BreastCancer, a multimedia CD-ROM guide to breast cancer prevention, detection,treatment, and resources, designed to be understood by the average layperson.

"Audiovisual presentations with full-color photographs guide theviewer through the information, addressing common questions and concerns,"said Bob Baker, president and CEO of AMC.

It is available in English or Spanish, and for Windows or Macintosh.There is a version for home and office use ($29.95, order no. U7AAAO) anda touch-screen version for educational and public-use settings ($49.95,U7AAB8).

The guide is being marketed by Time Life, with a portion of the profitsgoing to AMC. Order by calling Time Life Customer Services at 1-800-846-3843.

Recent Videos
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
Study findings reveal that patients with breast cancer reported overall improvement in their experience when receiving reflexology plus radiotherapy.
Patients undergoing radiotherapy for breast cancer were offered 15-minute nurse-led reflexology sessions to increase energy and reduce stress and pain.
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Ultra-hypofractionated radiation in those 65 years or older with early breast cancer yielded no ipsilateral recurrence after a 10-month follow-up.
The unclear role of hypofractionated radiation in older patients with early breast cancer in prior trials incentivized research for this group.
Patients with HR-positive, HER2-positive breast cancer and high-risk features may derive benefit from ovarian function suppression plus endocrine therapy.
Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.